Core Viewpoint - The company has completed the initial grant registration for its 2025 A-share stock option incentive plan, with a total of 24.7 million options granted at a price of 46.67 yuan per share [1] Group 1: Stock Option Plan Details - The registration date for the stock option incentive plan is November 14, 2025 [1] - A total of 226 individuals received the stock options, with 450,000 options being forfeited by 9 incentive recipients [1] - The maximum validity period for the incentive plan is 48 months, with the initial options divided into two exercise periods, each with a 50% exercise ratio [1] Group 2: Financial Implications - The total estimated expense to be amortized from 2025 to 2027 is 189.95 million yuan, broken down as follows: 33.79 million yuan in 2025, 115.09 million yuan in 2026, and 41.07 million yuan in 2027 [1]

Core Insights - The biopharmaceutical sector experienced a rise of 1.06% on November 13, with BoHui Innovation leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Stock Performance - BoHui Innovation (300318) closed at 8.17, with a significant increase of 13.47% and a trading volume of 1.4092 million shares [1] - Other notable performers included: - Sanofi (688336) at 73.00, up 6.57% with a trading volume of 137,200 shares [1] - Jinke (688670) at 23.36, up 5.23% with a trading volume of 124,300 shares [1] - Rongchang Bio (688331) at 89.00, up 3.37% with a trading volume of 68,500 shares [1] Capital Flow - The biopharmaceutical sector saw a net outflow of 211 million yuan from institutional investors, while retail investors contributed a net inflow of 86.65 million yuan [2] - The capital flow for specific stocks included: - Sanofi (688336) with a net inflow of 35.23 million yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 29.67 million yuan from institutional investors [3] - Long Spring High-tech (000661) experienced a net outflow of 59.78 million yuan from institutional investors [3]

Core Viewpoint - Junshi Biosciences is positioned as a comprehensive innovative pharmaceutical company with capabilities spanning drug discovery, clinical research, large-scale production, and commercialization, aiming for a global footprint while being rooted in China [2] Group 1: Company Overview - Junshi Biosciences has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received 11 indications in mainland China and is also approved in multiple countries including the US and EU [2] - The company is actively engaged in the development of early-stage products, with several expected to enter critical registration clinical trials by 2025 [2] - The company’s revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [7] Group 2: Recent Developments - Junshi Biosciences is collaborating with various research institutions and universities to develop vaccines, including those for monkeypox and Zika, which are currently in preclinical development [3] - A partnership has been established with Peking University and other institutions to jointly develop a recombinant protein vaccine for monkeypox [3] Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, reflecting a year-on-year growth of 42.06%, while the net profit attributable to the parent company was -596 million yuan, a 35.72% increase year-on-year [8] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% [8] Group 4: Market Activity - On November 13, Junshi Biosciences' stock rose by 2.38%, with a trading volume of 341 million yuan and a turnover rate of 1.14%, bringing the total market capitalization to 40.246 billion yuan [1] - The stock has seen a net inflow of 34.14 million yuan from major investors, indicating a slight increase in institutional interest [4][5]

君实生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：抗癌药物、抗癌治 癌、创新药、生物医药、精准医疗等。 截至9月30日，君实生物股东户数3.59万，较上期增加15.17%；人均流通股21361股，较上期减少 12.96%。2025年1月-9月，君实生物实现营业收入18.06亿元，同比增长42.06%；归母净利润-5.96亿元， 同比增长35.72%。 资金流向方面，主力资金净流入842.99万元，特大单买入384.09万元，占比4.73%，卖出119.26万元，占 比1.47%；大单买入1736.34万元，占比21.37%，卖出1158.19万元，占比14.25%。 君实生物今年以来股价涨42.92%，近5个交易日涨1.38%，近20日涨0.46%，近60日跌10.12%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等 ...

Group 1 - The core viewpoint of the article highlights that innovative pharmaceutical companies are transitioning from a "research and development investment phase" to a "commercialization harvest phase," driven by policy benefits, capital support, and clinical demand [1][4][5] Group 2 - Innovative pharmaceutical companies have reported impressive third-quarter results, with BeiGene achieving over 10 billion yuan in revenue, a year-on-year increase of 41.1%, and total revenue for the first three quarters reaching 27.595 billion yuan, up 44.2% [2] - Other leading innovative pharmaceutical companies also showed strong performance, with Hengrui Medicine reporting a revenue of 23.188 billion yuan for the first three quarters, a year-on-year growth of 14.85%, and WuXi AppTec achieving 32.857 billion yuan in revenue, up 18.61% [3] - The sales growth of core products, such as BeiGene's Zebrutinib and Junshi Biosciences' Toripalimab, is driving the performance of these companies, indicating a significant return on investment in research and development [5][6] Group 3 - The innovative drug sector is experiencing rapid growth, with a notable increase in business development (BD) transactions, totaling 92.03 billion USD in the first three quarters of 2025, reflecting a surge in licensing deals for domestic innovative drugs [6] - Analysts from Dongwu Securities express optimism about the innovative drug sector, predicting it will remain a key investment theme in the pharmaceutical industry through 2026, driven by the rising international status of Chinese innovative drug companies and a boom in BD transactions [7]

Core Viewpoint - The controlling shareholder and chairman of Junshi Biosciences, Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025 [1] Group 1: Shareholding Plan - Xiong Jun intends to purchase both A-shares and H-shares of Junshi Biosciences, with a minimum of RMB 50 million allocated for A-shares [1] - As of the announcement date, Xiong Jun has already acquired 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share purchase plan is still ongoing, and Xiong Jun will continue to buy shares as per the outlined plan during the implementation period [1]

Core Viewpoint - The chairman of Junshi Biosciences, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025, with a minimum of RMB 50 million allocated for A-shares [1] Group 1 - Mr. Xiong Jun has already purchased 100,000 A-shares, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share purchase will be conducted through the Shanghai Stock Exchange and the Hong Kong Stock Exchange, utilizing methods such as centralized bidding and block trading [1] - The increase in shareholding is part of a broader strategy to enhance investor confidence and demonstrate commitment to the company's future [1]

Core Viewpoint - The chairman of Junshi Biosciences, Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025, indicating confidence in the company's future performance [1] Group 1: Shareholding Plan - Xiong Jun intends to purchase both A-shares and H-shares, with a minimum of RMB 50 million allocated for A-shares [1] - As of the announcement date, Xiong Jun has already acquired 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share purchase plan is still ongoing, and Xiong Jun will continue to buy shares as per the outlined plan during the implementation period [1]

Core Viewpoint - The controlling shareholder and chairman of Junshi Biosciences, Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025 [1] Group 1: Shareholding Increase Plan - Xiong Jun intends to purchase both A-shares and H-shares of Junshi Biosciences, with a minimum of RMB 50 million allocated for A-shares [1] - As of the announcement date, Xiong Jun has already acquired 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share purchase plan is still ongoing, and Xiong Jun will continue to buy shares as per the outlined plan during the implementation period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於控股股東、實際控制人之一兼董事長增持股 份進展公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年11月10日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 重要内容提示： 上海君实生物医药科技股 ...